advertisement
Eye 134
Showing records 1 to 25 | Display all abstracts in Eye127332 The safety and effectiveness of optometrist-delivered selective laser trabeculoplasty
Swystun AG
Eye 2025; 39: 2284-2288
128368 Long-term follow-up of circumscribed iris melanomas treated by proton beam therapy
Lumbroso-Le Rouic L
Eye 2025; 39: 2599-2603
127146 Optic disc morphology in congenital glaucoma
Panigrahi A
Eye 2025; 39: 2211-2216
127128 Antioxidant-rich diets and glaucoma prevention: Insights from dietary oxidative balance scores in NHANES 2005-2008
Yang Y
Eye 2025; 39: 2527-2533
127538 Comparison of anterior segment optical coherence tomography versus technician led gonioscopy as a triage tool for anterior chamber angle status
Dhalla A
Eye 2025; 39: 2474-2478
127137 Association between leukocyte telomere length and incident glaucoma: A prospective UK biobank study
Yu J
Eye 2025; 39: 2176-2182
127332 The safety and effectiveness of optometrist-delivered selective laser trabeculoplasty
Swystun AG
Eye 2025; 39: 2284-2288
128747 Current and emerging strategies for myopia control: a narrative review of optical, pharmacological, behavioural, and adjunctive therapies
Maulvi FA
Eye 2025; 39: 2635-2644
127146 Optic disc morphology in congenital glaucoma
Panigrahi A
Eye 2025; 39: 2211-2216
127626 The effect of treatment of primary congenital glaucoma on meibomian glands and tear film
Elwehidy AS
Eye 2025; 39: 2277-2283
127928 The acceptance of ophthalmic artificial intelligence for eye diseases: a literature review and qualitative analysis
Ran AR
Eye 2025; 39: 2353-2362
127352 Does standalone phacoemulsification lower intraocular pressure in glaucomatous eyes? A systematic review and meta-analysis
Hussein O
Eye 2025; 39: 2518-2526
127460 One-year outcome of intense pulsed light therapy for refractory meibomian gland dysfunction in patients continuously exposed to topical glaucoma medications: a comparative study
Yang CC
Eye 2025; 39: 2460-2466
127652 Risk factor stratification in early-onset primary angle closure disease
Gupta S
Eye 2025; 39: 2604-2611
127178 PRESERFLO™ MicroShunt as a treatment option for highly increased intraocular pressure in primary open angle glaucoma and pseudoexfoliation glaucoma
Theilig T
Eye 2025; 39: 2253-2259
127404 Gonioscopy-assisted transluminal trabeculotomy outcomes in patients with highly advanced glaucoma
Magacho L
Eye 2025; 39: 2479-2484
128439 Non-surgical interventions for proliferative vitreoretinopathy-a systematic review
Hunter G
Eye 2025; 39: 2124-2142
127565 Outcomes of laser peripheral iridotomy in subgroups of primary angle closure disease eyes according to swept-source optical coherence tomography parameters
Wang LF
Eye 2025; 39: 2042-2050
127496 Cataract surgery with and without trabecular micro-bypass stent in primary angle-closure glaucoma: a multi-centre cohort study
Issa S
Eye 2025; 39: 2671-2677
128747 Current and emerging strategies for myopia control: a narrative review of optical, pharmacological, behavioural, and adjunctive therapies
Desai DT
Eye 2025; 39: 2635-2644
127928 The acceptance of ophthalmic artificial intelligence for eye diseases: a literature review and qualitative analysis
Lui CH
Eye 2025; 39: 2353-2362
127626 The effect of treatment of primary congenital glaucoma on meibomian glands and tear film
Abd Elfattah D
Eye 2025; 39: 2277-2283
127352 Does standalone phacoemulsification lower intraocular pressure in glaucomatous eyes? A systematic review and meta-analysis
Musleh A
Eye 2025; 39: 2518-2526
127460 One-year outcome of intense pulsed light therapy for refractory meibomian gland dysfunction in patients continuously exposed to topical glaucoma medications: a comparative study
Ko YC
Eye 2025; 39: 2460-2466
127652 Risk factor stratification in early-onset primary angle closure disease
Yadav SK
Eye 2025; 39: 2604-2611
